RJFSA
MLYS icon

Raymond James Financial Services Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Raymond James Financial Services Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,611
Closed -$126K – 3454
2023
Q4 		$126K Sell
14,611
-25,967
-64% -$204K ﹤0.01% 3096
2023
Q3 		$386K Buy
+40,578
New +$529K ﹤0.01% 2484

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Raymond James Financial Services Advisors's MLYS Position: Q1 2024 in Review

Raymond James Financial Services Advisors sold out of Mineralys Therapeutics (MLYS) in Q1 2024, closing a stake of 14,611 shares — an estimated $126K sold.

Raymond James Financial Services Advisors first reported a position in MLYS in Q3 2023 and held it in 2 quarters. The position peaked at $386K in Q3 2023. 92 funds tracked by Wall St. Rank hold MLYS as of Q1 2024.

  • Raymond James Financial Services Advisors reported no remaining Mineralys Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 14,611 Mineralys Therapeutics shares in Q1 2024, an estimated $126K.
  • Raymond James Financial Services Advisors first reported a position in Mineralys Therapeutics in Q3 2023 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Mineralys Therapeutics position peaked at $386K in Q3 2023.
  • 92 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2024, filed 22 Apr 2024.